RemedyOne, Author at RemedyOne

Want the Lowest-Net-Cost Drugs? Change Your Thinking on Disruption

It might seem like a lowest-net-cost formulary would be made up of clinically equivalent agents with the lowest overall cost. But in the complex world of drug pricing and pharmacy benefits, that is not the case. Lowest-net-cost formularies are a good way for organizations to lower their pharmacy spend. These formularies substitute clinically sound, chemically […]

Want the Lowest-Net-Cost Drugs? Change Your Thinking on Disruption Read More »

2021 Q4 RemedyOne Quarterly Pipeline Report

Clinical Insights / RemedyOne

Download our 2021 Q4 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest

2021 Q4 RemedyOne Quarterly Pipeline Report Read More »

Can the Vaccine Rollout Guide Us to More Efficient Health Care?

Clinical Insights, Formulary Management / RemedyOne

What the Covid vaccine taught us, and how we can be better. See this article as it originally appeared in Inc. With Covid-19 vaccine progress ahead of targets, it’s clear that the pharmaceutical industry has come through in a big way when the country needed it most. The vaccines were developed, approved, and distributed on

Can the Vaccine Rollout Guide Us to More Efficient Health Care? Read More »

Hospital Price Transparency Rule Not Enough to Lower Drug Prices

Clinical Insights, Formulary Management, Rebate Management / RemedyOne

Our healthcare system is extremely complex and increasing drug pricing transparency will be a big part of simplifying it in order to reduce costs. However, drug price data has to be easily digestible by consumers. The average American, and even healthcare professionals not directly involved in the payment and finance side of the business, are

Hospital Price Transparency Rule Not Enough to Lower Drug Prices Read More »

Uncovering Solutions for Affordable Drug Pricing

Formulary Management / RemedyOne

The House Committee on Oversight and Reform held a series of hearings to review findings from an in-depth investigation into drug pricing actions that was conducted last year with CEOs representing some of the largest and most profitable pharmaceutical manufacturers. As stated in the summary report of the investigation by Chairwoman Carolyn Maloney, “the drug

Uncovering Solutions for Affordable Drug Pricing Read More »

RemedyOne Drug Spotlight: Rukobia

Clinical Insights, Formulary Management / RemedyOne

Rukobia (fostemasavir) There are an estimated 2 million people living with the human immunodeficiency virus (HIV) in the United States. In 2018, there were close to 36,000 new cases of HIV diagnoses in the U.S. Since the introduction of antiretroviral therapy (ART), the HIV incidence has decreased as a result of decreased transmission and readily

RemedyOne Drug Spotlight: Rukobia Read More »

Navigating the Complex World of Generics and Authorized Generics

Clinical Insights, Formulary Management / RemedyOne

Executive Summary Today, generics are widely available and more regulated, with improved quality compared to that of the not-so-distant past. The savings from generic drugs has surpassed $265 billion since 2008, and ninety-three percent (93%) of generic prescriptions are filled at a cost of twenty dollars ($20) or less. Unfortunately, not all treatment categories have

Navigating the Complex World of Generics and Authorized Generics Read More »